Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Neoadjuvant Chemo Shows Comparable Data to Upfront Surgery in Ovarian Cancer

August 8th 2019

Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.

Harnessing Immune Response in Advanced Ovarian Cancer

August 5th 2019

Mian M. Shahzad, MD, PhD, discusses the use of checkpoint inhibition in advanced ovarian cancer.

Assessing Strategies and Challenges in Newly Diagnosed and Recurrent Ovarian Cancer

August 5th 2019

Jeannie Chern, MD, discusses developments with genetic testing in ovarian cancer and key trials in patients with recurrent disease.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Is Neoadjuvant Chemo Becoming Standard of Care for Advanced Ovarian Cancer?

August 2nd 2019

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer

August 1st 2019

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

Expert Explains Evolving Strategies in Ovarian Cancer

July 30th 2019

Robert M. Wenham, MD, discusses frontline management strategies for patients with newly diagnosed advanced ovarian cancer as well as the complexities of maintenance therapy.

The Future of Managing Gynecologic Cancer

July 30th 2019

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

PARP Inhibitor Mechanisms of Resistance

July 30th 2019

PARP Inhibitor Toxicity Management

July 30th 2019

Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

PARP Inhibitor Trial Updates

July 30th 2019

Treatment Options for Patients with BRCA1/2

July 30th 2019

Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019

Systemic Therapy Selection for Advanced EOC

July 30th 2019